PRAME and neoplasm: SF3B1 mutations were associated with Class 1 tumors (p < 0.0001), PRAME(+) status (p < 0.0001), decreased patient age (p < 0.0001), increased tumor diameter (p = 0.02), and brown iris color (p = 0.008).